Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2013

01-05-2013 | Brief Research Article

Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands

Authors: A. Fiorentino, M. Cozzolino, R. Caivano, P. Pedicini, C. Chiumento, C. Oliviero, S. Clemente, V. Fusco

Published in: Clinical and Translational Oncology | Issue 5/2013

Login to get access

Abstract

Purpose

To evaluate the dosimetric changes of parotid glands (PG) during a course of intensity-modulated radiotherapy (IMRT) in head and neck (H&N) cancer patients.

Methods

Ten patients with H&N cancer treated by IMRT were analyzed. The original treatment plan (CTplan) was transferred to cone-beam computed tomography (CBCT) acquired at the 15th and 20th treatment day (CBCTplan I and II, respectively). The PG mean dose (D mean), the dose to 50 % of the volume, and the percent of volume receiving 30 and 50 Gy were measured by the dose volume histogram.

Results

30 IMRT plans were evaluated (3 plans/patient). All dosimetric end points increased significantly for both PG only when CTplan was compared to CBCTplan I. The D mean increased significantly only for ipsilateral PG (p = 0.02) at week 3.

Conclusion

During a course of IMRT, CBCT is a feasible method to check the PG dosimetric variations. Perhaps, the 3rd week of radiotherapy could be considered as the time-check-point.
Literature
1.
Saarilahti K, Kouri M, Collan J et al (2006) Sparing of submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol 78:270–275PubMedCrossRef
2.
Robar JL, Day A, Clancey J et al (2007) Spatial and dosimetric variability of organs at risk in head-and-neck intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:1121–1130PubMedCrossRef
3.
4.
Barker JL Jr, Garden AS, Ang KK et al (2004) Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 59:960–970PubMedCrossRef
5.
Lee C, Langen KM, Lu W et al (2008) Assessment of parotid gland dose changes during head and neck cancer radiotherapy using daily megavoltage computed tomography and deformable image registration. Int J Radiat Oncol Biol Phys 71:1563–1571PubMedCrossRef
6.
Han C, Chen YJ, Liu A, Schultheiss TE, Wong JY (2008) Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys 70:1256–1262PubMedCrossRef
7.
Hansen EK, Bucci MK, Quivey JM, Weinberg V, Xia P (2006) Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 64:355–362PubMedCrossRef
8.
Ballivy O, Parker W, Vuong T, Shenouda G, Patrocinio H (2006) Impact of geometric uncertainties on the dose distribution during intensity modulated radiotherapy (IMRT) of head and neck cancer: the need for planning target volume (PTV) and planning organ at risk volume (PRV). Curr Oncol 13:108–115PubMed
9.
Wu Q, Chi Y, Chen PY, Krauss DJ, Yan D, Martinez A (2009) Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. Int J Radiat Oncol Biol Phys 75:924–932PubMedCrossRef
10.
Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S (2011) The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol 98:23–27PubMedCrossRef
11.
Bhide SA, Davies M, Burke K et al (2010) Weekly volume and dosimetric changes during chemoradiotherapy with intensity modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys 76(5):1360–1368PubMedCrossRef
12.
Nishimura Y, Nakamatsu K, Shibata T et al (2005) Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancer treated with IMRT. Jpn J Clin Oncol 35:375–379PubMedCrossRef
13.
Ricchetti F, Wu B, McNutt T et al (2011) Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 80:161–168PubMedCrossRef
14.
Vásquez Osorio EM, Hoogeman MS, Al-Mamgani A, Teguh DN, Levendag PC, Heijmen BJ (2008) Local anatomical changes in parotid and submandibular glands during radiotherapy for oropharynx cancer and correction with dose, studied in detail with non-rigid registration. Int J Radiat Oncol Biol Phys 70:875–882PubMedCrossRef
15.
Ding GX, Munro P, Pawlowski J, Malcom A, Coffey CW (2010) Reducing radiation exposure to patients from Kv-CBCT imaging. Radiother Oncol 97(3):585–592PubMedCrossRef
16.
Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66(4):981–991PubMedCrossRef
17.
Donovan E, Bleakley N, Denholm E, Breast Technology Group et al (2007) Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82(3):254–264PubMedCrossRef
18.
Ballivy O, Galiana Santamaría R, Lozano Borbalas A, Guedea Edo F (2008) Clinical application of intensity modulated radiotherapy for head and neck cancer. Clin Transl Oncol 10(7):407–414PubMedCrossRef
19.
Loo H, Fairfoul J, Chakrabarti A et al (2011) Tumor shrinkage and contour change during radiotherapy increase the dose to organs at risk but not the target volumes for head and neck cancer patients treated on the tomotherapy HiArtTM system. Clin Oncol 23:40–47CrossRef
20.
Castadot P, Geets X, Lee JA, Gregoire V (2011) Adaptive functional image guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? Radiother Oncol 101:343–350PubMedCrossRef
21.
Lee L, Le QT, Xing L (2008) Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file. Int J Radiat Oncol Biol Phys 70(2):634–644PubMedCrossRef
22.
Too S, Yin FF (2006) Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. Int J Radiat Oncol Biol Phys 66(5):1553–1561CrossRef
23.
Ho FK, Marchant T, Moore C et al (2012) Monitoring dosimetric impact of weight loss with kilovoltage (KV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82(3):e375–e382PubMedCrossRef
Metadata
Title
Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands
Authors
A. Fiorentino
M. Cozzolino
R. Caivano
P. Pedicini
C. Chiumento
C. Oliviero
S. Clemente
V. Fusco
Publication date
01-05-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0946-4

Other articles of this Issue 5/2013

Clinical and Translational Oncology 5/2013 Go to the issue

Research Article

Clinical and mutation analysis of four Chinese families with von Hippel-Lindau disease

Educational Series – Red Series

An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents

Research Article

Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib

Brief Research Article

Expression analysis of tumor-related genes involved in critical regulatory pathways in schwannomas

Educational Series – Blue Series

MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications

Research Article

Dose–volume histogram parameters for predicting radiation pneumonitis using receiver operating characteristic curve
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits